Clinical Trials | November 16, 2025
The observations are procedural in nature and will be responded to within the stipulated time
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
